Approximately 90% of melanomas retain wild-type p53, a characteristic that may help shape the development of novel treatment strategies. Here, we employed an adenoviral vector where transgene expression is controlled by p53 to deliver the p19 alternate reading frame (Arf) and interferon-b (IFNb) complementary DNAs in the B16 mouse model of melanoma. In vitro, cell death was enhanced by combined gene transfer (63.82±15.30% sub-G0 cells); yet introduction of a single gene resulted in significantly fewer hypoploid cells (37.73 ± 7.3% or 36.96 ± 11.58%, p19Arf or IFNb, respectively, Po0.05). Annexin V staining and caspase-3 cleavage indicate a cell death mechanism consistent with apoptosis. Using reverse transcriptase quantitative PCR, we show that key transcriptional targets of p53 were upregulated in the presence of p19Arf, although treatment with IFNb did not alter expression of the genes studied. In situ gene therapy revealed significant inhibition of subcutaneous tumors by IFNb (571 ± 25 mm 3 ) or the combination of p19Arf and IFNb (489 ± 124 mm 3 ) as compared with the LacZ control (1875 ± 33 mm 3 , Po0.001), whereas p19Arf yielded an intermediate result (1053±169 mm 3 , Po0.01 vs control). However, only the combination was associated with increased cell death and prolonged survival (Po0.01). As shown here, the combined transfer of p19Arf and IFNb using p53-responsive vectors enhanced cell death both in vitro and in vivo.
INTRODUCTION
When diagnosed early, melanoma often has a good prognosis, with surgery being the standard treatment. However, once cancerous cells spread from the original site, prognosis may evolve to a less favorable outcome due, in part, to its intrinsic resistance to conventional chemotherapy and radiotherapy. Average survival for patients with advanced metastatic melanoma is currently between 6 and 10 months, with little improvement despite considerable efforts over the past 30 years. 1 Treatment options for advanced melanoma vary from the standard single chemotherapeutic agent dacarbazine to immunotherapeutics, such as interleukin-2 and adjuvant interferon-alpha, although survival is extended by only a few months and in a limited number of patients when using these modalities. 2 Vemurafenib, the inhibitor of activated Braf V600E, has been shown to be quite effective, although issues of drug resistance and the need for combination therapy are currently being studied. 1 Therefore, continued efforts are needed for the development of novel, effective approaches for treatment of primary as well as metastatic melanoma.
Wild-type p53 is retained in B90% of melanoma cases, 3 implying that its tumor suppressor functions are inactivated. For example, loss of the p53 functional partner, alternate reading frame (Arf, p14ARF in humans and p19Arf in mice) occurs frequently in both inherited and sporadic cases of melanoma, 4, 5 and recent genome-wide association studies also confirmed Arf alterations as a marker for melanoma. 6 The Arf tumor suppressor protein is typically located in the nucleolus, interacts with Mdm2 and prevents Mdm2-mediated degradation of p53. [7] [8] [9] [10] In addition, Arf has been shown to have p53-independent tumor suppressor activity, indicating an alternative, nonlinear, relationship between them. 11 We have previously observed that restoration of Arf expression can cooperate to activate endogenous p53 in the B16 (B16F10) mouse melanoma model resulting in growth arrest, whereas gene transfer of p53 was completely ineffective. 12 Arf gene transfer may prove to be an interesting facet of melanoma treatment.
Interferon-b (IFNb), a member of the type-I interferon family, is directly implicated in tumor suppression as it provokes cell cycle arrest, induction of differentiation or apoptosis, as well as inhibition of angiogenesis [13] [14] [15] and also promotes an antitumor immune response by activating natural killer cells, stimulating macrophages, increasing major histocompatibility complex class I expression and activating dendritic cells. [16] [17] [18] [19] Binding of IFNb to the interferon type-I receptor activates the Jak/Stat pathway, which in turn directs the formation of the interferon-stimulated gene factor-3 complex. This complex binds to interferon response elements that are present in promoter regions of specific genes, leading to the expression of 4300 genes and, thus, the pleiotropic activities associated with IFNb. [20] [21] [22] The use of recombinant IFNb protein against advanced melanoma has an extensive history and is now well established. 23, 24 Even so, treatment with recombinant IFNb has been rather inefficient due, in part, to the short half-life of the protein in the circulation (B5 min) and consequent failure to sustain a therapeutic dose in different types of solid tumors. 25 Systemic toxicity associated with higher doses has further hampered the use of interferon in clinical trials. 26, 27 However, the use of recombinant viral vectors constitutively expressing IFNb has offered an alternative to the above mentioned drawbacks and shows promising antitumor activity, as seen in a variety of studies. [28] [29] [30] [31] [32] [33] [34] Strikingly, cross talk between the p53/Arf and IFN pathways has been reported. For example, both Arf and p53 are involved in IFNb-mediated antiviral and antiproliferative response [35] [36] [37] [38] due, in part, to the induction of p53 transcription. 35 However, it has been shown that induction of apoptosis by IFNb requires Arf but not p53; yet the cytostatic effect of IFNb was independent of Arf and p53. 36 We point out that these studies explored the involvement of the p53/Arf pathway upon treatment of cell lines with recombinant IFNb protein and did not employ viral vectors.
In our previous work, we have developed gene transfer vectors where expression of the gene of interest is controlled by p53. 12, [39] [40] [41] In this study, we employ our adenoviral vector with p53-responsive transgene expression (AdPG) to mediate gene transfer of p19Arf and IFNb complementary DNAs (cDNAs) to the B16 mouse melanoma cell line (p19Arf-deficient, p53-wild type). In this scenario, endogenous p53 would be recruited to drive the expression of p19Arf and IFNb. The interplay of these factors may provide positive feedback to promote vector expression, induce cell death and inhibit tumor progression.
MATERIALS AND METHODS

Vector construction
An adenoviral vector with transgene expression driven by p53 (AdPG) was described previously. 39 The synthetic promoter of this vector, referred to here as PG, contains a p53-responsive element, a minimal promoter and the first intron of the rabbit b-globin gene. This promoter was subcloned into a pEntr vector (Invitrogen, Carlsbad, CA, USA) and after that submitted to a second round of cloning for insertion of the cDNA of p19Arf (kindly provided by Charles Sherr, St Jude's Children's Hospital, Memphis, TN, USA), the cDNA of murine IFNb (kindly provided by Zhongyun Dong while at the MD Anderson Cancer Center, University of Texas, Houston, TX, USA) or firefly luciferase (isolated from pGL3, Promega, Madison, WI, USA). Expression cassettes contained in pEntrPGp19, pEntrPGIFNb and pEntrPGLUC were transferred, via site-directed recombination, to a promoterless adenoviral vector (pAd/PL-DEST, Gateway, Invitrogen), giving rise to AdPGp19 and AdPGIFNb. Details of the constructions are available upon request. The AdCMVLacZ vector was purchased from Invitrogen.
Cell lines and culture
The mouse melanoma cell line B16 (B16F10, ATCC CRL-6475) was transduced with a retrovirus containing the mouse, coxsackie adenovirus receptor (CARD1) and a neomycin-resistance gene (kindly provided by James DeGregori, Department of Biochemistry and Molecular Genetics, University of Colorado Cancer center, USA). 42 After 12 days of selection with G418 (500 mg ml À 1 ), the cell line B16mCAR was established. B16mCAR was maintained in Roswell Park Memorial Institute medium (Invitrogen) supplemented with 10% bovine calf serum (HyClone, Logan, UT, USA), 100 mg ml À 1 gentamycin, 50 mg ml À 1 ampicillin and 2.5 mg ml À 1 fungizone, at 37 1C with 5% CO 2 in a humidified incubator. HEK293 cells (293A, Invitrogen) were cultivated in Dulbecco's modified Eagle medium (Invitrogen), supplemented as described above and maintained in the same conditions as the B16mCAR cell line.
Virus production
Virus particles were obtained after transfection of linearized AdCMLacZ, AdPGLUC, AdPGp19 or AdPGIFNb plasmids into the HEK293 producer cells. Amplification was performed according to the protocol of Virapower Adenoviral Expression System (Invitrogen), followed by purification by the standard method of two rounds cesium chloride density gradient ultracentrifugation, followed by dialysis. Titration of adenoviral stocks was performed with the Adeno-X Rapid Titer Kit (Clontech, Mountain View, CA, USA); titer yields were 1. 
Identification of Annexin V-positive cells
Detection was performed according to the Annexin V apoptosis detection kit protocol (Santa Cruz Biotechnology, Santa Cruz, CA, USA). B16mCAR cells were transduced as described above, and after 72 h adherent and floating cells were collected and resuspended in binding buffer at a concentration of 1 Â 10 6 cells ml À 1 . One hundred microlitres (1 Â 10 5 cells) of this binding solution was transferred to a 5-ml culture tube and 1 ml Annexin-fluorescein isothiocyanate (0.2 mg ml À 1 ) plus 10 ml of propidium iodide (0.05 mg ml 
Western blot detection of caspase-3
Cells were transduced and, 72 h later, lysed in buffer (1 mM EDTA, 1 mM EGTA, 2 mM MgCl 2 , 5 mM KCl, 25 mM HEPES, 1 mM phenylmethanesulfonyl fluoride, 2 mM dithiothreitol, 0.1%Triton X-100) containing protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA). After 10 min on ice, samples were centrifuged at 10,000 g for 10 min to remove cellular debris. Cell lysates (40 mg) were heated in sample buffer, fractioned by SDSpolyacrylamide gel electrophoresis and transferred to Hybond polyvinylidene fluoride membranes (GE Healthcare Life Sciences, Uppsala, Sweden). Transfer efficiency was monitored by 0.5% Ponceau S staining of the membrane. The blotted membranes were blocked with 5% non-fat milk for 2 h at room temperature and probed with a polyclonal antibody against caspase-3 purchased from Cell Signaling (Danvers, MA, USA), and diluted at 1:1000. For the secondary antibody, a horseradish peroxidase-conjugated antibody was used and revealed using the ECL detection kit (GE Healthcare Life Sciences).
Reverse transcriptase quantitative PCR B16mCAR cells were plated in duplicate 10 cm dishes, 1.2 Â 10 6 cells each, and the next day transduced with AdPGLUC (MOI 1200), AdPGp19, AdPGIFNb or combination (MOI 600 per vector) and, 3 h later, 8 ml of fresh medium was added to the dishes. After 48 h of incubation, adherent cells were collected with 2 ml of Trizol reagent (Invitrogen) using a cell scraper. Total RNA was extracted following the fabricant's instructions and RNA concentration was determined by measuring absorbance at 260 nm. Extracted RNA quality was accessed by the protein and salt concentration, and by visualizing the 18 and 28S ribosomal RNA bands in an (1%) agarose gel. To avoid genomic DNA contamination, samples were treated with RNAse-free DNAse (Promega). Primers (Supplementary Table S1 ) were designed on the basis of the coding region closer to the 3 0 end of the gene, using the software Primer3 (http://www.frodo.wi.mit.edu/cgi-bin/ primer3/primer3_www.cgi). Primers are complimentary to sequences present in different exons (separated by introns), as predicted in sequences deposited at http://www.ncbi.nlm.nih.gov/nucleotide. Also, BLAST analysis (http://www.ncbi.nlm.nih.gov/blast) was done in order to predict, and thus avoid, nonspecific product formation. Three different reference genes were tested (b-actin, 28S and glyceraldehyde 3-phosphate dehydrogenase), and b-actin was determined to be the most stable among the samples. For the Bcl-2 and p53 genes, variants 1 and 2 were tested, and the one with the higher expression level was used. Efficiency of all designed primers was validated, being at minimum close to 100%. Total RNA (2 mg) was reverse transcribed using random primers and moloney murine leukemia virus reverse transcripatse (Invitrogen). Reaction conditions were 100 ng cDNA (final volume of 20 ml); 12.5 pmol each primer; 10 ml of Syber Green PCR Master Mix (Invitrogen). Amplification conditions consisted of denaturation at 95 1C for 15 min, followed by 40 cycles denaturation at 95 1C for 15 s, annealing at 60 1C for 1 min and extension at 72 1C for 1 min. All samples were tested in triplicate and analyzed by the 7500 Fast Software, version 2.05 (Applied Biosytems, Foster City, CA, USA). The 2 À DDCt method was used for gene expression quantification, and data is presented as foldchange in expression (log 2 ) as compared with the nontransduced B16mCAR condition.
Animal model
All procedures and conditions were approved in accordance to the guidelines of animal care and use by the Scientific and Ethics Committee of the Instituto do Corac¸ão and Hospital das Clínicas, University of São Paulo School of Medicine. Eight-week-old female C57BL/6 mice were injected subcutaneously with 5 Â 10 5 B16mCAR cells in the right flank. After 8-9 days, when tumors became palpable, animals were randomly assigned into five groups, namely p19 (AdPGp19), IFNb (AdPGIFNb), p19 þ IFNb (AdPGp19 and AdPGIFNb), and control groups LacZ (AdCMVLacZ) and Mock (phosphate-buffered saline only). The first intratumoral adenovirus injection was usually performed after 10 days when average tumor size reached B150 mm 3 (day 1) and injected again on days 3 and 6. All injections were done in a final volume of 100 ml (completed with 1 Â phosphate-buffered saline) using 5 Â 10 9 IU of each virus, except LacZ where 1 Â 10 10 IU was applied. Tumor size was measured with a caliper every 3 days starting at day 1 (before the first injection), and volume was calculated according to the formula: V (mm
. At 48 h after the last viral injections, three animals of each group were injected intraperitoneally with 100 mg kg À 1 bromodeoxyuridine (BrdU), maintained for an additional 4 h and then euthanized. Tumors were removed for immunohistochemistry and histological analyses and remaining animals submitted to long-term evaluation of tumor volume progression and survival time. When necessary, moribund animals were euthanized. This experiment was performed twice with similar results, although for clarity and brevity we show tumor progression from only one experiment (Mock n ¼ 5, LacZ n ¼ 6, p19 ¼ 4, IFNb n ¼ 6, p19 þ IFNb n ¼ 5) and survival analysis from both (Mock n ¼ 11, LacZ n ¼ 12, p19 n ¼ 11, IFNb n ¼ 13, p19 þ IFNb n ¼ 12).
Histological and immunohistological analyses
Segments of tumors were either fixed in 4% paraformaldehyde for BrdU and hematoxylin and eosin staining or frozen for terminal deoxynucleotidyl transferase-mediated 2 0 -deoxyuridine 5 0 -triphosphate-fluorescein isothiocyanate-FITC nick-end labeling. Tumors fixed in paraformaldehyde were embedded in paraffin, cut in sections (3-8 mm) and mounted on poly-L-lysine (Sigma)-coated slides. Slides were dewaxed in xylene and rehydrated in increasing ethanol concentrations. Detection of proliferating cells (BrdU) was done following the protocol supplied with the BrdU peroxidase staining kit (Zymed laboratories, South San Francisco, CA, USA), and hematoxylin and eosin staining performed according to standard procedures. Sections were analyzed by light microscopy (Leica DMLS, Wetzlar, Germany). Programmed cell death was assessed by terminal deoxynucleotidyl transferase-mediated 2 0 -deoxyuridine 5 0 -triphosphatefluorescein isothiocyanate-FITC nick-end labeling on samples embedded in tissue-freezing medium (Tissue-Tek/OCT, Sakura-Americas, Torrance, CA, USA), cut in sections (10-12 mm) with a Microm HM505E cryostat (Microm International, Walldorf, Germany) and mounted on poly-L-lysine (Sigma)-coated slides. Staining was performed following directions of the supplier (in situ cell-death detection kit, Fluorescein, Roche Applied Biosciences, Penzberg, Germany). Fluorescein-labeled cells were visualized by fluorescence microscopy (Nikon Eclipse E600, Osaka, Japan).
RESULTS
Transduction efficiency and validation of adenoviral vectors
Transduction of B16 cells with serotype 5 adenoviral vectors is known to be quite inefficient because of the lack of CAR expression. 43, 44 To circumvent this problem, B16 cells were transduced with a retroviral vector encoding a truncated version of murine CAR 42 and selected for G418 resistance. This cell line, now termed B16mCAR, can be transduced at a 90-100% efficiency using a MOI of 300 (Supplementary Figure S1) .
The cDNAs for p19Arf or murine IFNb were placed under the command of the synthetic p53-responsive promoter PGTxb, 39 referred to here as PG, and inserted in a serotype 5 adenoviral vector (Figure 1a) . Confirmation of expression from AdPGp19 was evaluated by immunofluorescence staining of transduced B16mCAR cells (Figure 1b) . Nucleolar localization of p19Arf was observed, as expected, only in cells transduced with AdPGp19, a finding that also suggests that the p53-dependent promoter was reliably transactivated.
To confirm expression of AdPGIFNb, B16mCAR cells were plated, transduced and supernatants collected every 24 h for 3 days. Presence of IFNb protein was assayed by enzyme-linked immunosorbent assay as shown in Figure 1c . When cells were transduced with the AdPGIFNb vector alone, conditioned supernatant contained B700 pg ml À 1 of IFNb (24 h) and remained constant at 48 h and 72 h. However, a slight reduction in cell viability together with diminished IFNb protein concentration was observed in the double-treated cells. As corroborated by the following assays, it is tempting to speculate that the loss of cell viability may have been due to interactions of p19Arf and IFNb.
Proof of the p53-dependent nature of our vectors containing the p53-responsive promoters has been accumulated through our previous studies. We point out that treatment of B16mCAR with pifithrin-a, an inhibitor of the transactivation function of p53, reduced the induction of AdPGIFNb expression upon further treatment with doxorubicin (a chemotherapeutic agent well known for its ability to provoke p53 function, data not shown). Together, these assays indicate that AdPG virus expression does indeed rely on p53.
In vitro assays reveal enhanced cell death upon combined p19Arf and IFNb gene transfer Cell cycle analysis of B16mCAR cells was performed at three different time points (48, 72 and 96 h) after transduction. When transduced by the combination of AdPGp19 and AdPGIFNb, we observed an accumulation of sub G0/G1 cells, which increased over time (63.92% at 96 h, Figure 2a and Supplementary Figure S2 ); yet individual gene transfer, p19Arf or IFNb, resulted in significantly less cell death (37.73% or 36.96%, respectively, Po0.01). This assay indicates that the combined treatment was more efficient in killing B16mCAR cells than was seen when using the individual vectors.
To better characterize the cell death mechanism, we measured Annexin V-PI double staining by fluorescence-activated cell sorting. Cells were transduced at a MOI of 300, and after 72 h collected for analysis. As shown in Figure 2b and Supplementary Figure S3 , double-transduced cells yielded 66.52% Annexin V-positive cells compared with 45.76% and 37.33% (AdPGIFNb and AdPGp19, respectively, Po0.01) with the single treatment. Cells transduced with the control vector, AdPGLUC, resulted in 14.2% of cells stained with Annexin V. This assay corroborates the cell cycle result and also suggests that cell death was consistent with apoptosis.
To deepen our understanding of the cell death mechanism observed in these experiments, we examined another marker associated with apopstosis, the cleavage of caspase-3 (an effector caspase activated in the late executioner phase of apoptosis). Cells were harvested 72 h after transduction and subjected to western blot analysis using an antibody capable of detecting both fulllength (35 kDa) and cleaved (19 kDa) caspase-3 proteins. As seen in Figure 2c , the cleavage products were more prevalent when the cells received virus treatment including IFNb. This result also suggests that the cell death mechanism was consistent with apoptosis.
Next, we used reverse transcriptase quantitative PCR to investigate the expression level of key molecular components of the p19Arf-Mdm2-p53 pathway. Cells were harvested 48 h after transduction, before total RNA was isolated and processed for the reverse transcriptase quantitative PCR assay. The p21Waf1, Mdm and Puma transcripts were significantly more abundant in the presence of exogenous p19Arf, although Bcl-2 was not significantly altered ( Figure 3 ). As expected, the p19Arf transcript was readily detected only in cells transduced with the AdPGp19 vector. However, the p53 transcript was not significantly altered upon gene transfer, suggesting that the presence of IFNb was not sufficient to induce expression of p53 in this assay. In fact, none of the target genes studied was altered by IFNb gene transfer. In addition, the combination of p19Arf and IFNb did not alter gene expression as compared with p19Arf gene transfer alone. These results suggest that introduction of p19Arf induced endogenous p53 activity, although the specific roles of p53, p19Arf and IFNb were not revealed by the analysis of this small selection of genes. Further studies will be required to elucidate the mechanism by which p19Arf and IFNb cooperate to enhance cell death.
Dual in situ gene therapy reduces tumor growth, induces apoptosis and extends overall survival We next evaluated whether p19Arf and IFNb gene transfer would impact tumor progression in vivo. B16mCAR cells were implanted subcutaneously in C57BL/6 mice and once tumors were established, in situ gene therapy was initiated. Tumors were injected with 5 Â 10 9 IU of each vector, except the LacZ control, which received 1 Â 10 10 infectious particles, on three occasions (days 1, 3 and 6). Samples for histological evaluation were collected after a follow-up of 2 days (n ¼ 3 per group, animals injected with BrdU 4 h before euthanasia), while the remainder of the animals were maintained for observation. Animals were euthanized when moribund or when tumors reached a volume of 2000 mm 3 . As shown in Figure 4a Histological analysis of tumors (hematoxylin and eosin) showed the presence of pyknotic/necrotic cells characterized by amorphous matrix deposition, and such areas were larger in extent in the single AdPGIFNb and dual-treated groups when compared with the other three groups (Supplementary Figure S4) . Normal B16 cell morphology (large cytoplasm/volumous nuclei) was present surrounding these areas of pyknotic/necrotic cells. Proliferating tumor cells, detected with an antibody against BrdU, were present in all groups but to a lesser extend in tumors where amorphous matrix deposition was observed (Supplementary Figure S5) . In contrast, terminal deoxynucleotidyl transferasemediated 2 0 -deoxyuridine 5 0 -triphosphate-fluorescein isothiocyanate-FITC nick-end labeling staining in tumor tissues showed that apoptotic cells were found in vastly greater number in the dualtreated tumor when compared with all other groups (Figure 4c) . Overall, both the single treatment with AdPGIFNb and the double treatment with AdPGp19 and AdPGIFNb inhibited tumor progression, but only the double treatment significantly increased survival and promoted massive apoptosis.
DISCUSSION
We have used recombinant adenoviral vectors where expression of the transgene is controlled by the transcriptional activity of p53 to deliver p19Arf and/or IFNb to a murine melanoma cell line. Transgene expression was reliable, indicating that the p53-responsive promoter was functional. We observed that the combined transfer of p19Arf and IFNb resulted in enhanced cell death, consistent with apoptosis, both in vitro and in vivo. The interplay of p53, p19Arf and IFNb appear to have cooperated to drive vector expression, induce cell death and retard tumor progression.
Viral vectors with transgene expression controlled by p53 have previously been developed in our lab. Starting with a retroviral vector, termed pCLPG, we showed that the level of transgene expression was superior to that seen with the parental pCL vector containing a constitutively active non-modified long terminal repeat. 41 We then introduced the p53 cDNA to the pCLPG vector, creating a positive feedback loop, where transgene expression is autoregulated, and showed that this vector was superior in retarding the proliferation of tumor cell lines as compared with constitutive expression of p53 from the parental vector. 40 We also developed a synthetic promoter that is responsive to p53, termed PGTxb (or simply PG), inserted this in an adenoviral vector and showed that transgene expression levels surpassed that of the widely used CMV promoter. 39 The pCLPG retroviral vector was also used to transfer the p19Arf cDNA to B16 and C6 (rat glioma, wild-type p53) cell lines. Reliable , and incubated for 48 h before purification of total RNA and processing for RT-qPCR. b-actin was used as the reference gene, but similar results were also observed using the 28S or glyceraldehyde 3-phosphate dehydrogenase genes. Data presented as fold-change (log 2 ) as compared with the non-transduced B16 murine coxsackie adenovirus receptor (mCAR) condition. Data represents the average and s.d. from triplicate PCR reactions derived from three independent biological experiments. *Po0.05, one-way analysis of variance, followed by Tukey's multi comparison post-test. expression of p19Arf was mediated by the pCLPG vector, suggesting the possibility that a positive feedback circuit may have been established (vector expression provides Arf that activates p53, which promotes vector expression and so on). Although quite efficient for the arrest of C6 cells, monotherapy with either p19Arf or nutlin-3 (a small molecule inhibitor of the p53-Mdm2 interaction) was only weakly able to activate endogenous p53 in B16. However, when combined, the gene and pharmacological therapies activated p53 function and induced the arrest of B16 cells, both in vitro and in vivo.
12 From these studies we learned that the p53-responsive vectors present an interesting option for Arf gene transfer and that p19Arf function may need to be complemented in order to bring about tumor cell inhibition.
In the present work, we observed that indeed p19Arf alone, although now in an adenoviral vector with transgene expression controlled by p53, was not an effective agent for the inhibition of B16mCAR proliferation and, consistent with our previous study, may require a second, cooperating agent. We reasoned that IFNb may be an interesting partner for p19Arf as reports in the literature have shown that the p53/Arf and IFN pathways interact. 35, 36 In our assays, the single treatment with AdPGIFNb was only moderately able to induce cell death; yet the combined treatment with AdPGp19 and AdPGIFNb did so much more efficiently. At this point, we cannot define the exact roles of p53, p19Arf and IFNb in the induction of death in B16mCAR cells, although such studies are underway.
Our in vivo study revealed significant inhibition of tumor progression by either AdPGIFNb or the double therapy. On the surface it may appear that either approach is equally capable of blocking tumor growth. However, the terminal deoxynucleotidyl transferase-mediated 2 0 -deoxyuridine 5 0 -triphosphate-fluorescein isothiocyanate-FITC nick-end labeling assay clearly showed massive cell death only with the dual treatment. That is to say, the treatment with AdPGIFNb alone may arrest the cells and prevent tumor development, but the combined treatment with AdPGp19 and AdPGIFNb killed tumor cells outright.
The design of the viral vectors may be improved by avoiding the need for two independent constructs as well as bypassing the dependence on CAR for transduction. The transfer of two cDNAs using a single vector can be easily accomplished using an internal ribosome entry site to mediate bicistronic expression from a single transcript. 45 In theory, this would ensure that all transduced cells receive and express both cDNAs in equal amounts. The use of fiber-modified adenoviral vectors, such as with the arginineglycine-aspartic acid tripeptide in the H1 loop of the knob protein, do not rely on CAR to mediate the virus-cell interaction, and therefore transduce a wide variety of cells that express a v integrins. 43, 44 Such constructs have been built by our lab and will be described elsewhere.
The work presented here was not designed to reveal the immunomodulatory function of IFNb, although we are currently studying this issue. Many reports in the literature show that in situ treatments involving IFNb do lead to immune protection through innate mechanisms, such as increased natural killer cell activity and infiltration of macrophages, 32, 46 and also through a lymphocyte-mediated tumor rejection by enhancing the cross presentation by dendritic cells and stimulating the cytotoxic functions of CD8 þ T cells. 47, 48 Gene transfer of both an immune-modulating gene and a tumor suppressor could prove to be quite interesting. The tumor suppressor would, in principle, restore the defective pathway (such as exogenous p19Arf activating endogenous p53), rendering the cell more susceptible to stimulators of cell death. The immunemodulating gene would then recruit and activate an antitumor immune response. In the case of IFNb, its pleiotropic activity would not only promote an immune response, but also modulate the mechanism of cell death, as exposure to IFNb was shown to reactivate caspase-8 activity and abrogate intrinsic resistance to anticancer drugs 49 or, as recently demonstrated, by inducing authophagy, thus counteracting its proapoptotic function. 50 It is tempting to speculate that cell death coupled with a strong immune-activating signal would be powerful allies in combating both the primary and metastatic lesions. Future studies will investigate whether the combined treatment with p19Arf and IFNb induces immunogenic cell death.
The use of vectors where transgene expression is controlled by p53 may create interplay between endogenous and exogenous components of the approach. Of particular interest will be the continued examination of the interactions of the p53/Arf and IFN pathways as well as the possibility that an antitumor immune response may be generated upon treatment with our vectors.
